TABLE 4.
Log-rank analysis and subdistribution HRs of freedom from late toxicities for patients who were or were not taking MHSs and were treated for prostate cancer with the use of definitive IMRT1
| Late toxicity | With events, n (%) | Free from toxicity, % (95% CI) | With events, n (%) | Free from toxicity, % (95% CI) | Log-rank P | sHR (95% CI) | P |
| Genitourinary | |||||||
| Grades 2–4 | 135 (7) | 91 (89, 92) | 13 (6) | 93 (87, 96) | 0.36 | 0.91 (0.51, 1.63) | 0.76 |
| Grades 3–4 | 24 (1) | 98 (97, 99) | 1 (1) | 99 (96, 100) | 0.87 | MNR2 | — |
| Gastrointestinal | |||||||
| Grades 2–4 | 287 (15) | 80 (77, 82) | 31 (14) | 84 (76, 89) | 0.43 | 0.91 (0.62, 1.33) | 0.62 |
| Grades 3–4 | 36 (2) | 97 (96, 98) | 5 (2) | 96 (89, 98) | 0.28 | 1.16 (0.45, 2.97) | 0.75 |
1
Columns on the left side (number of events, their 95% CIs, and the log-rank P values) of the table (log-rank tests) were unadjusted. Adjusted ratios are provided on the right side (sHRs and P values) of the table. IMRT, intensity-modulated radiation therapy; MHS, men’s health supplement; MNR, model not run; sHR, subdistribution HR.
2
Because there were too few events in the MHS group.